|
WO2012158818A2
(en)
|
2011-05-16 |
2012-11-22 |
Fabion Pharmaceuticals, Inc. |
Multi-specific fab fusion proteins and methods of use
|
|
BR112014004168A2
(pt)
|
2011-08-23 |
2017-12-12 |
Roche Glycart Ag |
anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, célula hospedeira procariótica ou eucariótica, método de produção de anticorpo e invenção
|
|
EP2904016B1
(en)
|
2012-10-08 |
2018-11-14 |
Roche Glycart AG |
Fc-free antibodies comprising two fab-fragments and methods of use
|
|
MX375359B
(es)
|
2013-02-26 |
2025-03-06 |
Roche Glycart Ag |
Moléculas biespecíficas de unión a antígeno activadoras de células t.
|
|
EP2789630A1
(en)
*
|
2013-04-09 |
2014-10-15 |
EngMab AG |
Bispecific antibodies against CD3e and ROR1
|
|
JP6464255B2
(ja)
|
2014-08-04 |
2019-02-06 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性ｔ細胞活性化抗原結合分子
|
|
RS61010B1
(sr)
|
2014-11-20 |
2020-11-30 |
Hoffmann La Roche |
Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3
|
|
SI3221357T1
(sl)
|
2014-11-20 |
2020-09-30 |
F. Hoffmann-La Roche Ag |
Pogoste lahke verige in načini uporabe
|
|
DK3221355T3
(da)
|
2014-11-20 |
2020-12-07 |
Hoffmann La Roche |
Kombinationsbehandling med T-celleaktiverende bispecifikke antigenbindende molekyler CD3 og folatreceptor 1 (FolR1) samt PD-1-aksebindende antagonister
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
EP3356410B1
(en)
|
2015-10-02 |
2021-10-20 |
F. Hoffmann-La Roche AG |
Bispecific anti-ceaxcd3 t cell activating antigen binding molecules
|
|
EA201891066A1
(ru)
|
2015-10-30 |
2018-10-31 |
ЭнБиИ-ТЕРАПЬЮТИКС АГ |
Антитела к ror1
|
|
EP4026848A1
(en)
|
2015-12-09 |
2022-07-13 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing the cytokine release syndrome
|
|
JP6949030B2
(ja)
|
2016-01-08 |
2021-10-13 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Ｐｄ−１軸結合アンタゴニスト及び抗ｃｅａ／抗ｃｄ３二重特異性抗体を用いたｃｅａ陽性がんの治療方法
|
|
SG11201806120WA
(en)
|
2016-01-20 |
2018-08-30 |
Scripps Research Inst |
Ror1 antibody compositions and related methods
|
|
CN109476756B
(zh)
|
2016-03-15 |
2022-05-31 |
埃泰美德(香港)有限公司 |
一种多特异性Fab融合蛋白及其用途
|
|
HRP20230528T1
(hr)
|
2016-03-22 |
2023-08-04 |
F. Hoffmann - La Roche Ag |
Bispecifične molekule t stanica aktivirane proteazom
|
|
ES2897217T3
(es)
*
|
2016-09-30 |
2022-02-28 |
Hoffmann La Roche |
Anticuerpos biespecíficos frente a p95HER2
|
|
AU2018250641B2
(en)
|
2017-04-11 |
2025-03-13 |
Inhibrx Biosciences, Inc. |
Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same
|
|
MX2019015057A
(es)
|
2017-06-23 |
2020-08-03 |
Velosbio Inc |
Inmunoconjugados de anticuerpos receptor huérfano similar al receptor tirosina cinasa 1 (ror1).
|
|
GB201710835D0
(en)
|
2017-07-05 |
2017-08-16 |
Ucl Business Plc |
ROR1 Antibodies
|
|
GB201710838D0
(en)
|
2017-07-05 |
2017-08-16 |
Ucl Business Plc |
Bispecific antibodies
|
|
GB201710836D0
(en)
|
2017-07-05 |
2017-08-16 |
Ucl Business Plc |
ROR1 Car T-Cells
|
|
WO2019016381A1
(en)
*
|
2017-07-20 |
2019-01-24 |
Nbe-Therapeutics Ag |
MULTISPECIFIC ANTIBODY PRODUCT BINDING TO DIFFERENT ROR1 EPITOPES
|
|
EP3665193A1
(en)
|
2017-08-07 |
2020-06-17 |
NBE Therapeutics AG |
Anthracycline-based antibody drug conjugates having high in vivo tolerability
|
|
CN107827984B
(zh)
*
|
2017-09-13 |
2021-03-16 |
张慧林 |
嵌合抗ROR1抗体Fab分子及其制备方法和应用
|
|
GB201721802D0
(en)
*
|
2017-12-22 |
2018-02-07 |
Almac Discovery Ltd |
Ror1-specific antigen binding molecules
|
|
JP7475275B2
(ja)
|
2018-02-08 |
2024-04-26 |
ジェネンテック， インコーポレイテッド |
二重特異性抗原結合分子及びその使用方法
|
|
TWI829667B
(zh)
*
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
|
MX2020010267A
(es)
|
2018-03-30 |
2020-11-06 |
Merus Nv |
Anticuerpo multivalente.
|
|
BR112020020604A2
(pt)
|
2018-04-11 |
2021-01-12 |
Inhibrx, Inc. |
Construções de polipeptídeo multiespecífico tendo ligação restrita de cd3 e métodos e usos relacionados
|
|
BR112020021269A2
(pt)
*
|
2018-04-18 |
2021-03-16 |
Exelixis, Inc. |
Construções de anticorpo anti-ror
|
|
WO2020023553A1
(en)
|
2018-07-24 |
2020-01-30 |
Inhibrx, Inc. |
Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
|
|
EP3847196A4
(en)
|
2018-09-07 |
2023-01-04 |
ITabMed (HK) Limited |
BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
|
|
EP3864045A2
(en)
|
2018-10-11 |
2021-08-18 |
Inhibrx, Inc. |
Dll3 single domain antibodies and therapeutic compositions thereof
|
|
WO2020076992A1
(en)
*
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
5t4 single domain antibodies and therapeutic compositions thereof
|
|
WO2020132810A1
(en)
|
2018-12-24 |
2020-07-02 |
Generon (Shanghai) Corporation Ltd. |
Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
|
|
WO2020254352A1
(en)
*
|
2019-06-19 |
2020-12-24 |
F. Hoffmann-La Roche Ag |
Method for the generation of a trivalent antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
|
|
SG11202112491WA
(en)
*
|
2019-07-31 |
2021-12-30 |
Hoffmann La Roche |
Antibodies binding to gprc5d
|
|
CN115380047A
(zh)
|
2020-01-29 |
2022-11-22 |
印希比股份有限公司 |
Cd28单结构域抗体及其多价和多特异性构建体
|
|
BR112022025856A2
(pt)
|
2020-06-19 |
2023-01-10 |
Hoffmann La Roche |
Anticorpo que se liga a cd3 e cd19, polinucleotídeo isolado, célula hospedeira, método de produção de um anticorpo que se liga a cd3 e cd19, composição farmacêutica, uso do anticorpo, método para tratar uma doença em um indivíduo e invenção
|
|
KR20230053602A
(ko)
*
|
2020-08-24 |
2023-04-21 |
에피맙 바이오테라퓨틱스 (에이치케이) 리미티드 |
항-ror1 항체 및 관련된 이중특이적 결합 단백질
|
|
EP3988568A1
(en)
*
|
2020-10-21 |
2022-04-27 |
Numab Therapeutics AG |
Combination treatment
|
|
CA3203831A1
(en)
*
|
2020-12-29 |
2022-07-07 |
Dongheon Lee |
Bi- or multi-specific antibody
|
|
MX2023009022A
(es)
*
|
2021-02-02 |
2023-10-23 |
Numab Therapeutics AG |
Anticuerpos multiespecificos con especificidad para ror1 y cd3.
|
|
CA3213632A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
|
JP2026507084A
(ja)
*
|
2023-02-23 |
2026-02-27 |
アダネイト， インコーポレイテッド |
抗ｃｄ３抗体およびそれを使用するための方法
|